Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ORIGIN4MB

Financiado

Cerrado

Uncovering the cell of origin of Group 4 Medulloblastoma

Medulloblastoma (MB) is the most common malignant paediatric brain tumour, affecting mostly infants and children, and to a lesser extent adults. It originates from neuronal stem or progenitor cell populations on the cerebellum or... ver más

31/03/2026

FUNDACAO CHAMPALIM...

157K€

Presupuesto del proyecto: 157K€

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-23

HORIZON-WIDERA-2022-TALENTS-04-01: Fostering balanced brain circulatio... ExpectedOutcome:This action will build on the MSCA Postdoctoral Fellowships 2022 action (HORIZON-MSC...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACAO CHAMPALIMAUD

156.78K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NOTCH PATHWAY IN GSC Role of Notch signaling pathway in Glioma Stem Cells Cerrado

Medulloblastoma Molecularly defined models of human childhood brain tumors 1M€ Cerrado

GAMNG Identification of the genetic and or epigenetic events that... 75K€ Cerrado

CancerHetero Dissection of tumor heterogeneity in vivo 2M€ Cerrado

GBM_Cellular_States Deciphering and targeting cellular states in glioblastoma 2M€ Cerrado

Notch pathway in GSC Role of Notch signaling pathway in Glioma Stem Cells 234K€ Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2023-10-23
Fecha Fin: 2026-03-31

Líder del proyecto

FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 157K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Medulloblastoma (MB) is the most common malignant paediatric brain tumour, affecting mostly infants and children, and to a lesser extent adults. It originates from neuronal stem or progenitor cell populations on the cerebellum or brainstem during development and/or childhood, comprising around 60% of childhood intracranial embryonal tumours. The main risk factors associated with this condition are heritable factors, including germline mutations in genes that regulate developmental signaling pathways in the cerebellum. MB are classified in 4 subgroups (Wnt, Sonic Hedgeghog (SHH), Group 3 and Group 4) according to their gene expression, cell of origin, methylation patterns and clinical features. Group 4 MB is the most common subgroup of MB, affecting approximately 40% of the patients with this condition. The cellular origins of Group 4 MB are still under debate; however, recent papers using single cell RNA sequencing showed that Group 4 MBs are characterized by the expression of transcription factors such as Eomesodermin(EOMES) and LIM/Homeobox protein 2(LHX2) genes expressed by granule upper rhombic lip progenitors, more specifically Unipolar Brush Cells(UBCs) that are born during cerebellar morphogenesis. Therefore, one can hypothesize that Group 4 MB originates from UBCs progenitors. The main goals of the ORIGIN4MB project are to uncover the cell of origin of Group 4 MB and to develop the first pre-clinical model of Group 4 MB, revealing unprecendented insights in MB biology. To this end we will use lineage tracing techniques, lentiviral in utero infection, in vivo imaging and post-mortem analysis. We will also validate if the generated mouse model is able to recapitulate the human disease. This validation will determine if this model could be used to develop new treatments for Group 4 MB, opening the door to new therapeutic avenues for those pedeatric patients, ultimately improving their quality of life.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores